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background
 
The value of regular surveillance for breast cancer in women with a genetic or familial
predisposition to breast cancer is currently unproven. We compared the efficacy of mag-
netic resonance imaging (MRI) with that of mammography for screening in this group
of high-risk women.
 
methods
 
Women who had a cumulative lifetime risk of breast cancer of 15 percent or more were
screened every six months with a clinical breast examination and once a year by mam-
mography and MRI, with independent readings. The characteristics of the cancers that
were detected were compared with the characteristics of those in two different age-
matched control groups.
 
results
 
We screened 1909 eligible women, including 358 carriers of germ-line mutations. With-
in a median follow-up period of 2.9 years, 51 tumors (44 invasive cancers, 6 ductal
carcinomas in situ, and 1 lymphoma) and 1 lobular carcinoma in situ were detected.
The sensitivity of clinical breast examination, mammography, and MRI for detecting
invasive breast cancer was 17.9 percent, 33.3 percent, and 79.5 percent, respectively,
and the specificity was 98.1 percent, 95.0 percent, and 89.8 percent, respectively. The
overall discriminating capacity of MRI was significantly better than that of mammog-
raphy (P<0.05). The proportion of invasive tumors that were 10 mm or less in diameter
was significantly greater in our surveillance group (43.2 percent) than in either control
group (14.0 percent [P<0.001] and 12.5 percent [P=0.04], respectively). The com-
bined incidence of positive axillary nodes and micrometastases in invasive cancers in
our study was 21.4 percent, as compared with 52.4 percent (P<0.001) and 56.4 percent
(P=0.001) in the two control groups.
 
conclusions
 
MRI appears to be more sensitive than mammography in detecting tumors in women
with an inherited susceptibility to breast cancer.
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he cumulative lifetime risk of
 
breast
 
 
 
cancer among Dutch women is
approximately 11 percent.
 
1
 
 A family his-
tory of breast cancer or the presence of a germ-line
mutation of the 
 
BRCA1
 
 or 
 
BRCA2
 
 gene increases
this risk considerably and is often associated with
a diagnosis at a young age.
 
2,3
 
 Among high-risk
women, the risk of breast cancer can be reduced by
prophylactic mastectomy,
 
4,5
 
 prophylactic oopho-
rectomy,
 
6,7
 
 or chemoprevention.
 
8
 
 Early diagnosis
as a result of intensive surveillance may also de-
crease the rate of death from breast cancer.
Randomized trials have shown that mammo-
graphic screening of all women who are between
50 and 70 years of age can reduce mortality from
breast cancer by about 25 percent.
 
9
 
 Although these
findings were recently disputed,
 
10
 
 there is a consen-
sus among clinicians that breast-cancer screening
of women in this age group is effective. Screening
is one of the main factors contributing to the de-
crease in mortality associated with breast cancer in
the Netherlands.
 
11
 
 However, there is no consensus
about the value of breast-cancer screening among
women who are 40 to 49 years old.
 
12-14
 
 One of the
reasons for the lack of agreement is the difficulty in
detecting tumors by mammographic screening
in younger women, who have denser breasts than
postmenopausal women.
 
15,16
 
 Although screening
is frequently offered to women with a genetic pre-
disposition to breast cancer who are under the age
of 50 years, the efficacy of this approach is unprov-
en. Preliminary results of surveillance by mammog-
raphy and clinical breast examination in such wom-
en showed that mammographic screening has a low
sensitivity for detecting tumors, especially in car-
riers of a 
 
BRCA
 
 mutation.
 
17-21
 
 Possible reasons,
apart from the high rate of growth of tumors in
women with such mutations, include the atypical
changes seen on screening mammograms and spe-
cific histopathological characteristics in carriers of
 
BRCA
 
 mutations, as compared with noncarriers of
the same age.
 
22-24
 
In a diagnostic setting, magnetic resonance im-
aging (MRI) is a sensitive method of breast imag-
ing, and it is virtually uninfluenced by breast den-
sity, but the specificity is variable and the costs are
high.
 
25-27
 
 Because MRI may improve the sensitiv-
ity of screening in women with a familial or genetic
predisposition to breast cancer, we prospectively
compared MRI with mammography for screening
women with such a predisposition in order to de-
termine whether screening with MRI facilitated
the early diagnosis of hereditary breast cancer.
 
study population
 
The design of our MRI screening study, in which
six subcommittees in different disciplines were in-
volved, has been described previously.
 
28
 
 Between
November 1, 1999, and October 1, 2003, 1952 wom-
en with a genetic risk of breast cancer were recruit-
ed for the study by six familial-cancer clinics in the
Netherlands. The six centers were Erasmus Medi-
cal Center–Daniel den Hoed Cancer Center, Rotter-
dam; the Netherlands Cancer Institute, Amsterdam;
University Medical Center Nijmegen, Nijmegen;
Leiden University Medical Center, Leiden; Universi-
ty Hospital Groningen, Groningen; and Free Uni-
versity Medical Center, Amsterdam. The study was
approved by the ethics committees of all the cen-
ters. All the women who participated gave written
informed consent.
The inclusion criteria for participation were
a cumulative lifetime risk of breast cancer of 15
percent or more owing to a familial or genetic pre-
disposition, according to the modified tables of
Claus et al.,
 
29
 
 and an age of 25 to 70 years. Women
could be tested at an age younger than 25 if they
had a family history of breast cancer diagnosed be-
fore the age of 30 years, since testing began at an
age 5 years younger than that at which the youngest
family member was found to have breast cancer.
Women with symptoms that were suggestive of
breast cancer or women who had a personal histo-
ry of breast cancer were excluded.
 
surveillance
 
Surveillance consisted of a clinical breast exami-
nation performed by an experienced physician ev-
ery six months and imaging studies performed an-
nually by experienced radiologists. The imaging
included a mammographic study (oblique and cra-
niocaudal views and, if necessary, compression
views or magnifications) and a dynamic breast MRI
with gadolinium-containing contrast medium ac-
cording to a standard protocol.
 
25
 
 Whenever pos-
sible, both imaging investigations were performed
on the same day or in the same time period, be-
tween day 5 and day 15 of the menstrual cycle. The
results of mammography and MRI were scored in
a standardized way, according to the Breast Imag-
ing Reporting and Data System (BI-RADS) classi-
fication,
 
30,31
 
 and the results were blinded so that
the two examinations were not linked. When one
of the examinations was scored as either BI-RADS
category 3 (“probably benign [i.e., uncertain] find-
t methods
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ing”) or category 0 (“need additional imaging eval-
uation”), further investigation by ultrasonography
with or without fine-needle aspiration was advised,
or mammography or MRI was repeated. When one
of the two examinations was scored as BI-RADS
category 4 (“suspicious abnormality”) or category
5 (“highly suggestive of malignancy”), a cytologic
or histologic evaluation of a biopsy specimen was
performed. When the results of mammography and
MRI were negative but the findings on clinical breast
examination were rated as uncertain or suspicious,
additional investigation was also performed. The
diagnosis of malignant tumors was based on the re-
sults of a histologic examination. One of the investi-
gators, an expert pathologist, reviewed all the biop-
sy specimens that formed the basis for the diagnosis
of breast cancer.
 
statistical analysis
 
The women were divided into three categories ac-
cording to the cumulative lifetime risk of breast
cancer, as follows: carriers of the 
 
BRCA1
 
 or 
 
BRCA2
 
or other mutations (cumulative lifetime risk, 50 to
85 percent), a high-risk group (risk, 30 to 49 per-
cent), and a moderate-risk group (risk, 15 to 29 per-
cent).
 
28,29
 
 The characteristics of the women in each
risk group were compared by analysis of variance
or Pearson’s chi-square test.
The rates of detection of breast cancer for the
group as a whole and for each of the three risk
groups were calculated, and a Poisson distribution
was assumed in order to calculate the 95 percent
confidence intervals. Person-years at risk were cal-
culated from the date of the first examination, ir-
respective of the type of examination, to the date
of detection of breast cancer, bilateral prophylac-
tic mastectomy, or death; the date that a patient
stopped surveillance; or the cutoff date for this
analysis (October 1, 2003). An “interval cancer”
was defined as a carcinoma detected between two
rounds of screening after initially negative find-
ings on screening. In our analysis, we defined
as positive a mammographic or MRI study with a
BI-RADS score of 0, 3, 4, or 5 and a clinical breast
examination that was classified as “uncertain” or
“suspicious,” because those were the results that
triggered an additional examination.
To compare the three different screening meth-
ods, we calculated the sensitivity, specificity, and
positive predictive value of each. The sensitivity used
is that of one screening method relative to the oth-
ers, meaning that a test result is a false negative
when a proven cancer (diagnosed on the basis of
a histologic examination) is detected in the interval
or by one of the other methods. Receiver-operat-
ing-characteristic (ROC) curves for the two imag-
ing methods were generated. The area under the
curve was used as an index in evaluating the inher-
ent capacity of a screening method to discriminate
between “positive” and “negative” cases. We used
a z-test to compare the area under the curve for the
results of mammography and MRI. For the analysis
of the screening variables, we used only the screen-
ing data that included the results of both mam-
mography and MRI.
To determine whether breast cancer was diag-
nosed by screening at a stage more favorable to
treatment, the characteristics of breast tumors de-
tected in the study group were compared with those
in two control groups. The first control group was
derived from all women who had breast cancers
diagnosed in 1998 in the Netherlands. These data
were obtained from the National Cancer Registry.
The second control group consisted of unselected
patients who had received a diagnosis of primary
breast cancer in Leiden or Rotterdam between 1996
and 2002 and who were participating in a prospec-
tive study of the prevalence of gene mutations.
 
32
 
Subjects in both control groups were matched for
age with the patients in the study group (in five-year
categories). From this series of consecutive pa-
tients in the second control group, we chose all the
unscreened patients who were between 25 and 60
years old and whose cumulative lifetime risk of
breast cancer was more than 15 percent because of
a family history of the disease — information that
was routinely recorded in this database. The differ-
ences in tumor characteristics between the study
group and the control groups were tested with the
use of Pearson’s chi-square test or the chi-square
test for trend. A two-sided P value of less than 0.05
was considered to indicate statistical significance.
All statistical analyses were performed with the use
of SPSS software (version 9.0).
 
study population
 
Of the women who were invited to participate in
the study, 90 percent agreed. Initially, 1952 women
were included; 8 withdrew from the study before
their first screening visit and another 35 were ex-
cluded because they ultimately proved not to be car-
riers in a family with a proven mutation and there-
results
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fore had less than a 15 percent cumulative lifetime
risk of breast cancer. Of the 1909 remaining wom-
en, 88 (4.6 percent) left the study or were lost to
surveillance before October 1, 2003; 65 of these 88
women underwent prophylactic mastectomy. An-
other 89 women (4.7 percent) remained under sur-
veillance but later refused screening by MRI, be-
cause of claustrophobia or for other reasons.
Table 1 lists the characteristics of the 1909 wom-
en according to risk category. The mean age at en-
 
* Women in the group with mutations were those with 
 
BRCA1, BRCA2, PTEN,
 
 or 
 
TP53
 
 genetic mutations. Women in the high-
risk group were those with a cumulative lifetime risk of 30 to 49 percent. Women in the moderate-risk group were those with 
a cumulative lifetime risk of 15 to 29 percent. CBE denotes clinical breast examination, and HRT hormone-replacement 
therapy. Percentages are based on the numbers of women with known data; numbers with missing data are also shown.
† P<0.001 for the difference among the three groups.
‡ Perimenopausal status was defined by the occurrence of the last menstruation between 2 and 12 months before entry 
into the study.
 
§ P=0.04 for the difference among the three groups.
 
Table 1. Characteristics of Participating Women at Study Entry, According to Risk Group.*
Characteristic
Mutation Carriers
(N=358)
High-Risk Group
(N=1052)
Moderate-Risk Group
(N=499)
Total
(N=1909)
 
Mean age — yr† 38 41 40 40 
Previous screening — no. (%)
No screening 56 (16) 161 (16) 72 (15) 289 (15)
Only CBE 10 (3) 17 (2) 13 (3) 40 (2)
Imaging (with or without CBE)
≤1 yr before entry 189 (53) 543 (52) 268 (54) 1000 (53)
>1–2 yr before entry 79 (22) 259 (25) 111 (22) 449 (24)
>2 yr before entry 17 (5) 46 (4) 23 (5) 86 (5)
Time unknown 2 (1) 8 (1) 4 (1) 14 (1)
Unknown 5 18 8 31 
Menopausal status — no. (%)†
Premenopausal 244 (72) 754 (76) 376 (78) 1365 (75)
Perimenopausal‡ 5 (2) 34 (3) 15 (3) 54 (3)
Postmenopausal 20 (6) 121 (12) 52 (11) 193 (11)
Postmenopausal after oophorectomy 66 (19) 42 (4) 12 (3) 120 (7)
Posthysterectomy 3 (1) 48 (5) 24 (5) 75 (4)
Unknown 20 53 29 102 
Hormonal contraceptive use — no. (%)
Never 40 (12) 108 (11) 45 (10) 193 (10)
Past 167 (50) 567 (56) 276 (58) 1010 (56)
Present 128 (38) 329 (33) 154 (32) 611 (34)
Unknown 23 48 24 95 
HRT use — no. (%)§
Never 291 (87) 932 (92) 436 (92) 1659 (90)
Past 19 (6) 44 (4) 19 (4) 82 (5)
Present 25 (7) 38 (4) 19 (4) 82 (5)
Unknown 23 38 25 86
Oophorectomy — no. (%)†
No 276 (78) 1000 (96) 477 (97) 1753 (93)
Yes 77 (22) 41 (4) 13 (3) 131 (7)
Unknown 5 11 9 25
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try was 40 years (range, 19 to 72). Within the group
of 358 carriers of pathogenic mutations, 276 had
a 
 
BRCA1
 
 mutation, 77 had a 
 
BRCA2
 
 mutation, 1 had
both a 
 
BRCA1 
 
and a 
 
BRCA2
 
 mutation, 2 had a 
 
PTEN
 
mutation, and 2 had a 
 
TP53
 
 mutation.
 
breast cancers
 
From November 1, 1999, to October 1, 2003, 51
malignant tumors (44 invasive breast cancers,
6 ductal carcinomas in situ, and 1 non-Hodgkin’s
lymphoma) were detected (Fig. 1), during a medi-
an follow-up period of 2.9 years (mean 2.7, range,
0.1 to 3.9 years); 1 lobular carcinoma in situ was also
found. Table 2 shows the detection rate for the whole
group and separately for the different risk groups.
The overall rate of detection for all breast cancers
(invasive plus in situ) was 9.5 per 1000 woman-
years at risk (95 percent confidence interval, 7.1
to 12.3), with the highest rate (26.5 per 1000) in the
group of women who were carriers of the 
 
BRCA1,
BRCA2, PTEN, 
 
and 
 
TP53
 
 mutations.
 
performance of the screening methods
 
Table 3 shows the results with the three screening
methods. Of the 50 breast cancers that were detect-
ed, 5 were excluded from the analysis (Table 3). The
45 cancers that were evaluated in the comparison
of the methods included 4 interval cancers (i.e., can-
cers detected between two episodes of screening).
The first was symptomatic (30 mm in diameter,
node-negative), detected seven months after screen-
ing by imaging and clinical breast examination and
one month after screening by clinical breast exam-
ination only. The second (4 mm, node-negative) was
detected in a specimen from a prophylactic mastec-
tomy. The third was symptomatic (45 mm, node-
negative) and was detected seven months after
screening by imaging; the fourth, also symptomatic
 
Figure 1. Women at Increased Risk for Breast Cancer Enrolled and Tumors Detected.
 
A total of 1952 women were enrolled, of whom 1909 were eligible for this analysis.
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* CI denotes confidence interval. Rates shown are per 1000 woman-years at risk.
 
Table 2. Detection of Cases of Breast Cancer (Including Ductal Carcinoma in Situ) According to Risk Group.
Risk Group
No. of
Women
Woman-Years
at Risk
No. of Cases Detected
by Screening
No. of Cases Detected
between Screenings Rate of Detection (95% CI)*
 
Total Invasive Total Invasive All Cancers Invasive Cancers
 
no./1000
 
Mutation carriers 358 867 19 16 4 4 26.5 (15.3–39.4) 23.1 (14.1–35.6)
High-risk group 1052 2968 15 15 1 1 5.4 (3.1–8.8) 5.4 (3.1–8.8)
Moderate-risk group 499 1414 11 8 7.8 (3.9–13.9) 5.7 (2.4–11.1)
Total 1909 5249 45 39 5 5 9.5 (7.1–12.3) 8.4 (6.1–11.3)
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(13 mm, with isolated tumor cells in a lymph node),
was detected three months after screening by im-
aging.
Overall, 32 breast cancers were found by MRI
(22 of these were not visible on mammography),
whereas 13 were missed by MRI (8 of the 13 were
visible on mammography, including 5 ductal carci-
nomas in situ; 4 were interval cancers; and 1 tumor
was detected only by clinical breast examination).
In this group of 45 breast cancers, mammographic
screening detected 18 tumors (10 of these were vis-
ible by MRI) and missed 27 tumors (including the
22 that were visible on MRI, the 4 interval cancers,
and the 1 that was detected only by clinical breast
examination).
With respect to all breast cancers (invasive and
ductal carcinoma in situ), the sensitivity of clini-
cal breast examination, mammography, and MRI
was 17.8 percent, 40.0 percent, and 71.1 percent,
respectively, when the BI-RADS score was 3 or high-
er (Table 3). For invasive cancers only, the respec-
tive percentages were 17.9 percent, 33.3 percent,
and 79.5 percent. The specificity was 98.1 percent
for clinical breast examination, 95.0 percent for
mammography, and 89.8 percent for MRI.
Of the 41 cancers found by screening, 22 were
detected at the first imaging screening in the study;
of the women in whom cancer was detected, 16 had
undergone mammographic screening before the
start of the study. Two of the interval cancers were
 
* The results have been calculated on the basis of data on 45 of the 50 cancers. The reasons that five cases were omitted are as follows. In three 
cases, neither MRI nor mammography was performed (in two of these cases the women became pregnant, and in one case the woman refused 
MRI). In the fourth case, a tumor was detected on an additional mammogram, after a screening mammogram had been classified as Breast 
Imaging Reporting and Data System (BI-RADS) 0, but at a different location from the first lesion. The fifth cancer was detected at a screening 
visit that consisted of only a clinical breast examination. The cumulative number of true positive results is the number of cancers found at a specific 
BI-RADS level or higher; sensitivity is the percentage of cancers with a positive test result at a specific BI-RADS level or higher (the cumulative 
number of true positive results divided by the total number of cancers); specificity is the percentage of negative test results in women without 
a cancer; PPV is the percentage of true positive test results in women who ultimately appeared to have cancer, at a specific BI-RADS level or 
 
higher (the cumulative number of true positive test results divided by the cumulative number of tests).
 
Table 3. Sensitivity, Specificity, and Positive Predictive Value (PPV) of the Three Screening Methods.*
Screening Method 
and BI-RADS Cutoff
No. of
Tests
No. of
Breast
Cancers
Cumulative
No. of Tests
Cumulative
No. of True
Positive Results Sensitivity (%)
Specificity
(%)
PPV
(%)
No. of 
Biopsies
Performed
 
Any
Breast
Cancer
Invasive
Breast
Cancer
Clinical breast examination
Suspicious 6 3 6 3 6.7 7.7 99.9 50.0 4
Probably benign 77 5 83 8 17.8 17.9 98.1 9.6 8
Negative 3862 37 3945 45 100 100 0 1.1 55
Mammography
5 (highly suggestive) 3 3 3 3 6.7 7.7 100 100 3
4 (suspicious) 20 8 23 11 24.4 20.5 99.7 47.8 8
0 (need additional imaging) 32 4 55 15 33.3 28.2 99.0 27.3 9
3 (probably benign) 170 3 225 18 40.0 33.3 95.0 8.0 5
2 (benign) 240 2 465 20 44.4 38.5 89.2 4.3 4
1 (negative) 3704 25 4169 45 100 100 0 1.1 38
MRI
5 (highly suggestive) 10 6 10 6 13.3 15.4 99.9 60.0 7
4 (suspicious) 55 15 65 21 46.6 51.3 98.9 32.3 22
0 (need additional imaging) 112 8 177 29 64.4 71.8 96.4 16.4 15
3 (probably benign) 275 3 452 32 71.1 79.5 89.8 7.1 12
2 (benign) 383 1 835 33 73.3 82.1 80.6 4.0 0
1 (negative) 3334 12 4169 45 100 100 0 1.1 11
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detected after the first imaging screening, and two
others after a subsequent imaging screening. The
sensitivity of mammography was 37.5 percent for
the first screening and 42.9 percent for subsequent
screening (P=0.71). The sensitivity of MRI was 79.2
percent for the first screening and 61.9 percent
for subsequent screening (P=0.20).
Among the 83 clinical breast examinations with
findings that were judged as probably benign or sus-
picious, or highly suggestive of cancer, 8 cases of
malignant disease were confirmed, for a positive
predictive value of 9.6 percent (Table 3). Among the
225 mammograms with findings categorized as
BI-RADS 3 or higher, 18 cases of malignant disease
were confirmed, for a positive predictive value of
8.0 percent. A total of 32 cancers were confirmed
among 452 MRI screenings with such findings,
for a positive predictive value of 7.1 percent (Ta-
ble 3). With a cutoff level of BI-RADS 4, the sensi-
tivity for both imaging methods decreased, whereas
the specificity increased.
To evaluate the discriminating capacity of the
imaging methods, we generated ROC curves (Fig.
2). The area under the curve was 0.686 for mam-
mography and 0.827 for MRI; the difference be-
tween the areas was 0.141 (95 percent confidence
interval, 0.020 to 0.262; P<0.05).
 
additional investigations
 
Ultrasonography was performed 889 times in 627
different women according to the protocol. Fine-
needle aspiration was carried out 312 times: 267
times in combination with ultrasonography and
45 times with palpation. Biopsy was performed
85 times in 82 women and showed malignant dis-
ease in 50 cases and 1 lobular carcinoma in situ,
making the rate of positive histologic findings 60.0
percent. Sixty-seven of these 85 biopsies were per-
formed after a screening visit at which both MRI
and mammography were performed. Of the 25 bi-
opsies in women who had mammographic find-
ings with a score of 3 or higher, 7 (28.0 percent)
showed no cancer. Of the 56 biopsies in women
who had MRI findings with a score of 3 or higher,
24 (42.9 percent) showed no cancer (Table 3). One
of the 51 tumors was found in a specimen from
a prophylactic mastectomy.
 
tumor characteristics
 
Table 4 compares the characteristics of tumors
found in the study group with those of tumors in
the two age-matched control groups. In the study
group, 19 of the 44 women with an invasive breast
cancer (43.2 percent) had a small tumor (≤10 mm
in diameter) — a proportion that was significantly
higher than that in the first control group (14.0 per-
cent, P<0.001) or the second control group (12.5
percent, P=0.04). Six of 42 invasive tumors (14.3
percent) with known axillary status in the study
group were node-positive and 3 (7.1 percent) had
micrometastases (combined total, 21.4 percent).
This rate was significantly lower than those in both
control groups, in which the rates of node-positive
cancer were 52.4 percent (P<0.001) and 56.4 per-
cent (P=0.001), respectively. There were no major
differences between the study and control groups
with respect to histologic features, with the excep-
tion of a relatively high incidence of the medullary
type in the study group (11.3 percent, vs. 1.8 per-
cent in the first control group). In the study group,
a high proportion of grade 1 tumors were in wom-
en at high risk (68.8 percent) or moderate risk
(75.0 percent); however, the group of women with
 
BRCA1
 
, 
 
BRCA2
 
, or other mutations had a high per-
centage of grade 3 tumors (63.2 percent), in addi-
tion to a high percentage of tumors that were neg-
ative for steroid receptors (Table 4).
 
disease-free and overall survival
 
In the study group, none of the 50 patients with
breast cancer (44 with invasive cancer and 6 with
ductal carcinoma in situ) died before the end of the
study period; the total follow-up after diagnosis was
87.6 woman-years for these 50 patients (median,
1.5 years). Contralateral breast cancer occurred in
one patient. The patient with non-Hodgkin’s lym-
phoma died.
In this prospective study, we compared the effica-
cy of mammographic and MRI screening for breast
cancer in women with a family history of the dis-
ease or a genetic predisposition to breast cancer.
Among the women examined by both methods at
the same screening visit, we detected 45 breast can-
cers (including 6 ductal carcinomas in situ): 32 by
MRI (sensitivity, 71.1 percent) and 18 by mammog-
raphy (40.0 percent); five other patients were ex-
cluded from this comparison for various reasons
(Table 3). Thus, the sensitivity of MRI was higher
than that of mammography, but both the specifici-
ty and positive predictive value of MRI were lower.
In our sensitivity and specificity calculations, we
discussion
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defined lesions that were in BI-RADS category 3 and
higher as positive, but most other authors have in-
cluded in their calculations only lesions in BI-RADS
categories 4 and 5 as positive.
 
21,33,34
 
 If we had fol-
lowed that policy, the sensitivity would have been
24.4 percent for mammography and 46.6 percent
for MRI, in accord with the higher sensitivity pre-
viously reported for MRI.
 
21,33,35,36
 
 However, the
previous studies enrolled small groups of wom-
en, included some retrospective data,
 
35
 
 evaluated
heterogeneous groups that included women with
previous breast cancers,
 
21,33,36
 
 or had a plan for
follow-up after a suspicious finding on MRI that
differed from the follow-up plan for a suspicious
mammographic finding.
 
33
 
 All these factors might
have artificially increased the sensitivity of MRI. We
also investigated sensitivity in relation to specificity
as determined by ROC curves, showing that the
area under the curve was significantly higher for
MRI than for mammography; this means that MRI
screening could better discriminate between ma-
lignant and benign cases.
When we included only invasive breast cancers,
the difference between the sensitivity of the MRI
and mammography (79.5 percent vs. 33.3 percent)
was even greater than the difference overall (71.1
percent vs. 40.0 percent). MRI detected 20 cancers
(including 1 ductal carcinoma in situ) that were not
found by mammography or clinical breast exami-
nation. The stage of these 20 cancers was favor-
able; 11 of the 19 invasive tumors were smaller
than 10 mm, and only 1 was associated with a pos-
itive node.
Another important matter that we addressed
was the best method for detecting carcinoma in situ.
Our study showed that mammography had a high-
er sensitivity than MRI for detecting ductal carcino-
ma in situ: 83 percent (five out of six cancers detect-
ed), as compared with 17 percent (one out of six)
for MRI (P=0.22).
To investigate whether screening improves the
chance of diagnosing breast cancer at an early
stage, we compared the distribution of tumor stag-
es in our study with the distribution in two external
control groups. The first group consisted of age-
matched women in a database of all breast cancers
diagnosed in 1998 in the Netherlands. A drawback
of this group is that we had no information about
whether or not they had been screened or the fami-
ly history. Therefore, we added a second control
group from a prospective population-based study
of the prevalence of mutations in patients with
breast cancer. From this group, we selected all pa-
tients with an age and a family history of breast
cancer that were similar to the women in our sur-
veillance study. The tumors in our study group were
significantly smaller and were less likely to be
node-positive than those in the two control groups.
Most screening studies (without MRI) in high-
risk women have shown a higher incidence of pos-
itive nodes (30 to 45 percent) than we found (21
percent).
 
17,18,37
 
 Moreover, Kollias et al.
 
38
 
 found no
 
Figure 2. Receiver-Operating-Characteristic Curves for Mammography and MRI. 
 
The difference between the area under the curve (AUC) for mammography and the AUC for MRI was 0.141 (95 percent 
confidence interval, 0.020 to 0.262; P<0.05).
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* Percentages are based on the numbers of women with known data; numbers with missing data are not shown. In the control groups, 
zero denotes none, and the dash denotes not analyzed.
† There were 16 
 
BRCA-1
 
–related tumors (including 1 ductal carcinoma in situ), 6 
 
BRCA-2
 
–related tumors (including 1 ductal carcinoma in situ), 
and 1 
 
PTEN
 
-related tumor (ductal carcinoma in situ).
‡ P<0.001 for the comparison with the National Cancer Registry control group.
§ P=0.04 for the comparison with control group 2.
¶ Nodal biopsy was not performed in two cases in the study group.
¿ P=0.001 for the comparison with control group 2.
**Histologic status was unknown in some cases in the study group.
 
††P=0.01 for the comparison with control group 2.
 
Table 4. Characteristics of Women with Breast Cancer and Breast Cancers Detected in the Three Risk Groups and in the Two Control Groups.*
Characteristic
Mutation
Carriers†
High-Risk
Group
Moderate-Risk
Group Total Screened
Control Group 1
(National Cancer
Registry)
Control Group 2
(Prospective Study)
 
No. of women 23 16 11 50 1500 45
 
number of cancers (percent)
 
Age at diagnosis
20–29 yr 2 (8.7) 0 0 2 (4.0) 60 (4.0) 3 (6.7)
30–39 yr 13 (56.5) 5 (31.3) 1 (9.1) 19 (38.0) 570 (38.0) 13 (28.9)
40–49 yr 6 (26.1) 7 (43.7) 7 (63.6) 20 (40.0) 600 (40.0) 21 (46.6)
50–69 yr 2 (8.7) 4 (25.0) 3 (27.3) 9 (18.0) 270 (18.0) 8 (17.8)
Tumor size
Ductal carcinoma in situ 3 (13.0) 0 3 (27.3) 6 (12.0) 120 (8.0)
 
—
 
Invasive tumors
≤1 cm 7 (35.0) 8 (50.0) 4 (50.0) 19 (43.2)‡§ 193 (14.0) 5 (12.5)
1–2 cm 6 (30.0) 5 (31.2) 3 (37.5) 14 (31.8) 508 (36.8) 15 (40.0)
>2 cm 7 (35.0) 3 (18.8) 1 (12.5) 11 (25.0) 679 (49.2) 19 (47.5)
Nodal status¶
Negative 12 (63.2) 9 (60.0) 7 (87.5) 28 (66.7)‡¿ 657 (47.6) 17 (43.6)
Isolated cells 3 (15.8) 2 (13.3) 0 5 (11.9) — —
Positive 2 (10.5) 3 (20.0) 1 (12.5) 6 (14.3) 723 (52.4) 22 (56.4)
Micrometastasis (0.2–2.0 mm) 2 (10.5) 1 (6.7) 0 3 (7.1) — —
Histologic type
Ductal 14 (70.0) 11 (68.7) 5 (62.5) 30 (68.2) 1146 (83.0) —
Lobular 1 (5.0) 1 (6.3) 2 (25.0) 4 (9.1) 128 (9.3) —
Tubular 1 (5.0) 2 (12.4) 1 (12.5) 4 (9.1) 34 (2.6) —
Medullary 4 (20.0) 1 (6.3) 0 5 (11.3) 25 (1.8) —
Adenoid cystic 0 1 (6.3) 0 1 (2.3) 1 (0.7) —
Other 0 0 0 0 46 (3.3) —
Histologic grade**
Grade 1 2 (10.5) 11 (68.8) 6 (75.0) 19 (44.2)‡†† 99 (11.0) 4 (10.8)
Grade 2 5 (26.3) 1 (6.2) 2 (25.0) 8 (18.6) 339 (37.7) 14 (37.8)
Grade 3 12 (63.2) 4 (25.0) 0 16 (37.2) 462 (51.3) 19 (51.4)
Estrogen-receptor status**
Positive 6 (33.3) 11 (73.3) 7 (87.5) 24 (58.5) — 20 (60.6)
Negative 12 (66.7) 4 (26.7) 1 (12.5) 17 (41.5) — 13 (39.4)
Progesterone-receptor status**
Positive 7 (36.8) 11 (73.3) 7 (87.5) 25 (59.5) — 14 (46.7)
Negative 12 (63.2) 4 (26.7) 1 (12.5) 17 (40.5) — 16 (53.3)
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significant differences in the size or grade of inva-
sive tumors or in lymph-node status between wom-
en who had symptoms of cancer and women whose
cancers had been found on screening by mammog-
raphy. So we may conclude that MRI screening did
indeed contribute to the early detection of heredi-
tary breast cancer.
However, larger tumors (>2 cm in diameter)
were found more often in the women with 
 
BRCA1,
BRCA2, PTEN, 
 
and
 
 TP53
 
 mutations than in the other
two risk groups in our study, suggesting that more
frequent screening is needed for women with these
mutations. A drawback of MRI screening is that
it has a lower specificity than mammography, and
as a result, MRI will generate more findings judged
as uncertain, which require short-term follow-up
or additional investigations.
 
39
 
 In our study, screen-
ing by MRI led to twice as many unneeded addi-
tional examinations as did mammography (420
vs. 207) and three times as many unneeded biop-
sies (24 vs. 7).
In conclusion, our study shows that the screen-
ing program we used, especially MRI screening, can
detect breast cancer at an early stage in women at
risk for breast cancer.
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